Impact of Vericiguat on Hemodynamics of Heart Failure
Heart Failure
About this trial
This is an interventional basic science trial for Heart Failure
Eligibility Criteria
Inclusion Criteria: Adults 18 years of age or greater with New York Heart Association functional class II, III, or IV HFrEF with left ventricular ejection fraction < 45% within 12 months of enrollment; elevated brain natriuretic peptide level (BNP) within 30 days of enrollment; and history of worsening congestion, defined as a HF-hospitalization within 6 months of enrollment or increase in diuretic therapy without hospitalization within three months of enrollment. Exclusion Criteria: systolic blood pressure (SBP) below 100mmHg; use of long-acting nitrates, soluble guanylate cyclase stimulators, or phosphodiesterase type 5 inhibitors; use of intravenous inotropes or implantable left ventricular assist devices; use of anticoagulants with an inability to temporarily hold these medications for procedures or to keep the international normalized ratio < 2.5 units; uncontrolled arrhythmias; noncardiac factors that may limit the ability to exercise (e.g. severe osteoarthritis, peripheral vascular disease, severe pulmonary disease); and pregnancy.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Active Comparator
Placebo Comparator
Intervention
Control
Participants will be administered the drug vericiguat
Participants will be administered a placebo